Welcome to Divine life, Divine, Divine life, Divine life energy, Life energy, Guruji, Divine Energy, Divinity, Divine power, extraordinary powers, Unique human, Spirituality, Spiritual power, Trance, Zero Field, Enlightenment, Enlighten, Divine Blessings, Land transformation, Cashew tree, Cashew nuts, Human transformation, Chlorophyll B, Chlorophyll content, biochemical change in plants, photo chemical change in plants, Hormonal change in plants, unique structural and functional body, Destiny, CranioSacral rhythm, Diaphragm, CranioSacral system, CSF, Cerebrospinal fluid, craniosacral pulse, Physiology, Unique physiology, extraordinary man, Spiritual man, Spiritual Guru, Spiritual Guruji

Genetics

Microbial Genetics

Plant Genetics

Microbial Genetics

Staphylococcus Aureus

Nocardis Otitidis

Pseudomonas Aeruginosa

Serratia Marcescens

Enterobacter Aerogenes

Klebsiella Pneumoniae

Microbial Identification
(16S rDNA)

Klebsiella pneumoniae ATCC 15380


PROJECT REPORT

NAME OF SCIENTIST:
Mr. Mahendra Kumar Trivedi

SERVICE:
DNA FINGERPRINTING SERVICE (BY RAPD)

SERVICE NO.:
DF 53

Project Title	DNA Fingerprinting by RAPD Analysis
Cat#:	CSER 48
Name of Scientist:	Mr. Mahendra Kumar Trivedi
Institute:	Life Energies ltd, Mumbai.
Sample name:	Klebsiella pneumonia ATCC 15380

Objective:

The objective of this project is to Genotype five samples (CONTROL Versus TREATED- A, A1, B, B1) of the same line with five primers on Klebsiella pneumonia ATCC 15380.

Job Requirement:

Isolation of genomic DNA from Klebsiella pneumonia samples.
Generating RAPD-Fingerprinting profiles showing Polymorphic bands with five RAPD primers

Gram-positive material and primers

Three series of Inoculums (Control, Series A and Series B) were prepared for Klebsiella pneumonia. The Control series was procured from Bangalore Genei while the Series "A" and series 'B' were handed over to Mr. Mahendra Kumar Trivedi in sealed tubes on 23rd January 2008 during his visit to our R&D facility at Bangalore. On the same day, we provided one isolated room to Mr. Trivedi where he subjected the Series 'A' and Series 'B' to his treatment modality.

Whilst handing over these cultures to Mr. M. K. Trivedi for treatment purposes, optimum precautions were taken to avoid the contamination.

After the presumed treatment, Mr. Trivedi returned the samples to Ms. Bindu Damodaran (Designation - Executive Manager - Microbiology) in the same condition as handed over to him in an hour's time on the same day.

We did not know the treatment modality as it was kept confidential throughout the project.

MATERIALS & METHODS:

Sub culturing of treated samples.

1% Inoculum from two treated tubes (series A and series B) was taken and inoculated to fresh 5 ml medium and incubated at 37 C with 160 rpm for 18 hrs and labelled as series A1 and B1 respectively. The cultures were spun down and genomic DNA was isolated.

Genomic DNA was isolated using Ultrapure Genomic DNA prep Kit (Cat# KT 83).

Steps Involved:

Genomic DNA was isolated from Klebsiella pneumonia samples (Control, Treated A, Treated B provided by Mr. M. K. Trivedi and sub cultured samples Treated A1, Treated B1 provided by Bangalore Genei) using Ultrapure Genomic DNA prep Kit (Cat# KT 83).
Performed RAPD reactions using five RAPD primers (RBA Series used separately) to find polymorphism between control and treated samples under PCR conditions as mentioned:

Cycle condition:

94°C	94°C	35°C	72°C	94°C	38°C	72°C	72°C
7 min	60 sec	60 sec	120 sec	60 sec	60 sec	90 sec	7 min
	8 cycles			35 cycles

12 of PCR products were loaded on to 1.5 % agarose gel and resolved by electrophoresis. The gel was subsequently stained with ethidium bromide and viewed under UV-light. Photographs were documented subsequently (attached).
Polymorphic DNA bands are marked by arrows on the copy of the report.

Fig. 1. RAPD Profile of Klebsiella pneumonia samples Generated using Genei
RAPD primer RBA 5A, RBA 10A & RBA 15A.

Lane Description:

1: Control
2: Treated A
3: Treated A.1
4: Treated B
5: Treated B.1
M:100 bp Ladder (GeneiTM) Cat # RMBD19S;

Fig. 2. RAPD Profile of Klebsiella pneumonia samples Generated using Genei
RAPD primer RBA 21A & RBA 22A.

Lane Description:

1: Control
2: Treated A
3: Treated A.1
4: Treated B
5: Treated B.1
M:100 bp Ladder (GeneiTM) Cat # RMBD19S;

Calculation:
	A/ Bx100 = Percent polymorphism

Where,
	A= Polymorphic bands in treated plant B= No of bands in control

Sl. No	Bands scored	Description	Primer
1	18	Eleven bands are Common to Control and Treated samples; One band is unique to Control sample; Two bands are unique to Treated sample A; One band is unique to Treated sample A1; One band is unique to Treated sample B; Two bands are unique to Treated sample B1.	RBA 5A
2	15	Five bands are Common to Control and Treated samples; Three bands are unique to Control sample; One band is unique to Treated sample A; No band is unique to Treated sample A1; No band is unique to Treated sample B; No band is unique to Treated sample B1.	RBA 10A
3	12	Eight bands are Common to Control and Treated samples; One band is unique to Control sample; One band is unique to Treated sample A; No band is unique to Treated sample A1; No band is unique to Treated sample B; No band is unique to Treated sample B1.	RBA 15A
4	15	Thirteen bands are Common to Control and Treated samples; No band is unique to Control sample; No band is unique to Treated sample A; No band is unique to Treated sample A1; No band is unique to Treated sample B; No band is unique to Treated sample B1.	RBA 21A
5	14	Five bands are Common to Control and Treated samples; One band is unique to Control sample; One band is unique to Treated sample A; No band is unique to Treated sample A1; Two bands are unique to Treated sample B; No band is unique to Treated sample B1.	RBA 22A

RESULTS & DISCUSSION:

Control & Treated sample A

1. The level of true polymorphism between Control & Treated sample A was evaluated at 18 % with RBA 5A primer.

2. The level of true polymorphism between Control & Treated sample A was evaluated at 30 % with RBA 10A primer.

3. The level of true polymorphism between Control & Treated sample A was evaluated at 18 % with RBA 15A primer.

4. The level of true polymorphism between Control & Treated sample A was evaluated at 0 % with RBA 21A primer.

5. The level of true polymorphism between Control & Treated sample A was evaluated at 13 % with RBA 22A primer.

Control & Treated sample A1

6. The level of true polymorphism between Control & Treated sample A1 was evaluated at 12 % with RBA 5A primer.

7. The level of true polymorphism between Control & Treated sample A1 was evaluated at 15 % with RBA 10A primer.

8. The level of true polymorphism between Control & Treated sample A1 was evaluated at 27 % with RBA 15A primer.

9. The level of true polymorphism between Control & Treated sample A1 was evaluated at 6 % with RBA 21A primer.

10. The level of true polymorphism between Control & Treated sample A1 was evaluated at 6 % with RBA 22A primer.

Control & Treated sample B

11. The level of true polymorphism between Control & Treated sample B was evaluated at 12 % with RBA 5A primer.

12. The level of true polymorphism between Control & Treated sample B was evaluated at 15 % with RBA 10A primer.

13. The level of true polymorphism between Control & Treated sample B was evaluated at 27 % with RBA 15A primer.

14. The level of true polymorphism between Control & Treated sample B was evaluated at 0 % with RBA 21A primer.

15. The level of true polymorphism between Control & Treated sample B was evaluated at 20 % with RBA 22A primer.

Control & Treated sample B1

16. The level of true polymorphism between Control & Treated sample B1 was evaluated at 18 % with RBA 5A primer.

17. The level of true polymorphism between Control & Treated sample B1 was evaluated at 23 % with RBA 10A primer.

18. The level of true polymorphism between Control & Treated sample B1 was evaluated at 9 % with RBA 15A primer.

19. The level of true polymorphism between Control & Treated sample B1 was evaluated at 0 % with RBA 21A primer.

20. The level of true polymorphism between Control & Treated sample B1 was evaluated at 6 % with RBA 22A primer.

Treated sample A & Treated sample A1

21. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 18 % with RBA 5A primer.

22. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 10 % with RBA 10A primer.

23. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 11 % with RBA 15A primer.

24. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 0 % with RBA 21A primer.

25. The level of true polymorphism between Treated sample A & Treated sample A1 was evaluated at 10 % with RBA 21A primer.

Treated sample B & Treated sample B1

26. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 18 % with RBA 5A primer.

27. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 0 % with RBA 10A primer.

28. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 0 % with RBA 15A primer.

29. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 0 % with RBA 21A primer.

30. The level of true polymorphism between Treated sample B & Treated sample B1 was evaluated at 20 % with RBA 22A primer.

Treated sample A & Treated sample B

31. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 6 % with RBA 5A primer.

32. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 15 % with RBA 10A primer.

33. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 9 % with RBA 15A primer.

34. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 0 % with RBA 21A primer.

35. The level of true polymorphism between Treated sample A & Treated sample B was evaluated at 5 % with RBA 22A primer.

Treated sample A1 & Treated sample B1

36. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 6 % with RBA 5A primer.

37. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 8 % with RBA 10A primer.

38. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 18 % with RBA 15A primer.

39. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 6 % with RBA 21A primer.

40. The level of true polymorphism between Treated sample A1 & Treated sample B1 was evaluated at 0 % with RBA 22A primer.

CONCLUSION:

Polymorphism was detected between Control & Treated sample A. The percentage of true polymorphism observed between Control & Treated samples of Klebsiella pneumonia sample is on an average 15%.
Polymorphism was detected between Control & Treated sample A1. The percentage of true polymorphism observed between Control & Treated samples of Klebsiella pneumonia sample is on an average 13%.
Polymorphism was detected between Control & Treated sample B. The percentage of true polymorphism observed between Control & Treated samples of Klebsiella pneumonia sample is on an average 14%.
Polymorphism was detected between Control & Treated sample B1. The percentage of true polymorphism observed between Control & Treated samples of Klebsiella pneumonia sample is on an average 11%.
Polymorphism was detected between Treated sample A & Treated sample A1. The percentage of true polymorphism observed between Control & Treated samples of Klebsiella pneumonia sample is on an average 9%.
Polymorphism was detected between Treated sample B & Treated sample B1. The percentage of true polymorphism observed between Control & Treated samples of Klebsiella pneumonia sample is on an average 7%.
Polymorphism was detected between Treated sample A & Treated sample B. The percentage of true polymorphism observed between Control & Treated samples of Klebsiella pneumonia sample is on an average 7%.
Polymorphism was detected between Treated sample A1 & Treated sample B1. The percentage of true polymorphism observed between Control & Treated samples of Klebsiella pneumonia sample is on an average 7%.
The treatment modality of Mr. Mahendra Kumar Trivedi is not known to us, the company is only concerned about detecting DNA polymorphism in Control & Treated lines of Klebsiella pneumonia samples.

Approved by: Dr. Avijit Roy

Manager R & D
Bangalore Genei.

Download Original K. PNEUMONIA DNA FINGERPRINTING REPORT - PDF (438 kb)

Print this page

RELATED REPORTS :

ANTIBIOTIC SENSITIVITY/BIOCHEMICAL REACTIONS REPORT

MICROBIAL IDENTIFICATION (16S rDNA) REPORT